Dr. Neal D. Shore
/content/dam/asset-migration/headshots/us-doctor-headshots/US_Urology_Head_shot_GA_Neal_D_Shore.jpg

Neal D. Shore

Neal D. Shore
Neal D.
Shore
MD, FACS
US CMO of Urology and Surgery

Languages spoken

English

Expert in

Urology, Urologic Surgery

Interested in

Prostate and Bladder Cancer, Erectile Dysfunction, Voiding Disorders, BPH Trials

Overview

Centers

Myrtle Beach (Urology)
Myrtle Beach (Urology)

823 82nd Parkway
Myrtle Beach, South Carolina 29572

33.75536030345918, -78.81765881349443
/us/our-locations/myrtle-beach-gs1
Myrtle Beach (Urology)
Myrtle Beach (Urology)

5046 Hwy. 17 Bypass Suite 200
Myrtle Beach, South Carolina 29588

33.75536030345918, -78.81765881349443
/us/our-locations/myrtle-beach-gs4

Specializes in

Benign Prostatic Hyperplasia
Speciality
Speciality/Cancer
Speciality/Cancer/Benign Prostatic Hyperplasia
Bladder Cancer
Condition
Condition/Cancer
Condition/Cancer/Bladder cancer
Prostate Cancer
Condition
Condition/Cancer
Condition/Cancer/Prostate cancer
Genitourinary cancer
Condition
Condition/Cancer
Condition/Cancer/Genitourinary cancer
Gynecological cancer
Condition
Condition/Cancer
Condition/Cancer/Gynecological cancer
Kidney cancer
Condition
Condition/Cancer
Condition/Cancer/Kidney cancer
Penile cancer
Condition
Condition/Cancer
Condition/Cancer/Penile cancer
Prostate cancer
Condition
Condition/Cancer
Condition/Cancer/Prostate cancer
Testicular cancer
Condition
Condition/Cancer
Condition/Cancer/Testicular cancer
Ureter cancer
Condition
Condition/Cancer
Condition/Cancer/Ureter cancer
Urethral cancer
Condition
Condition/Cancer
Condition/Cancer/Urethral cancer

Treatments

Benign Prostatic Hyperplasia (BPH)
Speciality
Speciality/Cancer
Speciality/Cancer/Benign Prostatic Hyperplasia
CT scanning
Service
Service/Cancer
Service/Cancer/Diagnostics imaging scans
Service/Cancer/Diagnostics imaging scans/CT scanning
Diagnostics
Service
Service/Cancer
Service/Cancer/Diagnostics
Genitourinary cancer
Condition
Condition/Cancer
Condition/Cancer/Genitourinary cancer
Gynecological cancer
Condition
Condition/Cancer
Condition/Cancer/Gynecological cancer
Kidney cancer
Condition
Condition/Cancer
Condition/Cancer/Kidney cancer
Pathology
Service
Service/Cancer
Service/Cancer/Pathology
Penile cancer
Condition
Condition/Cancer
Condition/Cancer/Penile cancer
Prostate cancer
Condition
Condition/Cancer
Condition/Cancer/Prostate cancer
Surgery
Service
Service/Cancer
Service/Cancer/Surgery
Testicular Cancer
Condition
Condition/Cancer
Condition/Cancer/Testicular cancer
Ureter cancer
Condition
Condition/Cancer
Condition/Cancer/Ureter cancer
Urethral cancer
Condition
Condition/Cancer
Condition/Cancer/Urethral cancer

Dr. Neal Shore graduated both Duke University and Duke University Medical School. He completed his general surgery/urology residence at New York Hospital-Cornell Medical Center/Memorial Sloan Kettering Cancer Center.

He is the Medical Director, for the Carolina Urologic Research Center. He practices with Atlantic Urology Clinics in Myrtle Beach, South Carolina. Dr Shore has conducted more than 400 clinical trials, focusing mainly for GU Oncology indications.

He is the Chief Medical Officer, Surgery/Urology, for GenesisCare, US. He has more than 250 peer reviewed publications and numerous book chapters. He serves on the SITC Guidelines Committee for Bladder Cancer as well as the boards of the Bladder Cancer Advocacy Network and the Duke Global Health Institute. He is the Chair of the LUGPA Education Committee.

He is on the editorial boards of Reviews in Urology, Urology Times, Chemotherapy Advisor, OncLive, PLOS ONE, Urology Practice, World Journal of Urology, and also serves as Editor, Everyday Urology-Oncology.

He is a Fellow of the American College of Surgeons.  

Careerpositions

Career positions

Career position(s)

  • GenesisCare, National Urology Research Director, Myrtle Beach, SC

Past position(s)

  • Carolina Urologic Research Center/Grand Strand Urology - Medical Director, Myrtle Beach, SC
  • Urology Oncology Consortium - Founding Member, Myrtle Beach, SC
  • CUSP - Founding Member, Myrtle Beach, SC

Education

Universities

Residencies

  • Duke University, BA, Public Policy Sciences, Durham, NC
  • Duke University School of Medicine, Durham, NC
  • The New York Hospital, Cornell Medical Center, General Surgery, New York, NY
  • The New York Hospital, Cornell Medical Center, Chief Resident, Urology, New York, NY

Professional association

Publications

  • Androgen Deprivation Therapy in Prostate Cancer: Balancing the Risks and Benefits. View presentation
  • Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303. View presentation
  • Final 5-Year Outcomes of the Multicenter Randomized Sham-Controlled Trial of a Water Vapor Thermal Therapy for Treatment of Moderate to Severe Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. View presentation
  • IMPACT OF DAROLUTAMIDE ON LOCAL SYMPTOMS IN PATIENTS WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER. View publication
  • Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer. View publication

Presentations

DD-MVAC is the new SOC
Neal D. Shore, 2021, OncLive
View presentation

PSMA – RLT is here
Neal D. Shore, 2021, OncLive
View presentation

Is triplet therapy the new SOC?
Neal D. Shore, 2021, OncLive
View presentation

HERO phase III trial: Results comparing relugolix, an oral GnRH receptor antagonist, versus leuprolide acetate for advanced prostate cancer.
Neal D. Shore, 2020, ASCO Annual Meeting

Efficacy of enzalutamide (ENZA) + androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC) by pattern of metastatic spread: ARCHES post hoc analyses.
Neal D. Shore, 2020, ASCO Annual Meeting

Phase Ib study: APL-1202 (APL) in combination with Bacillus Calmette-Guerin (BCG) in recurrent non-muscle invasive bladder cancer (NMIBC).
Neal D. Shore, 2020, ASCO Annual Meeting

Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for nonmetastatic castration-resistant prostate cancer (nmCRPC).
Neal D. Shore, 2020, ASCO Annual Meeting

Pembrolizumab (pembro) plus enzalutamide (enza) in patients (pts) with abiraterone acetate (abi)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort C efficacy, safety, and biomarker results.
Neal D. Shore, 2020, ASCO Annual Meeting

DaroACT: Darolutamide and enzalutamide effects on physical and neurocognitive function and daily activity in patients with castration-resistant prostate cancer (CRPC).
Neal D. Shore, 2020, ASCO Annual Meeting

TALAPRO-2: a placebo-controlled phase III study of talazoparib (TALA) plus enzalutamide (ENZA) for patients with first-line metastatic castration-resistant prostate cancer (mCRPC).
Neal D. Shore, 2020, ASCO Annual Meeting

Pembrolizumab Plus Enzalutamide in Abiraterone-Pretreated Patients with Metastatic Castration-Resistant Prostate Cancer: Updated Results from Keynote-365 Cohort C
Yu, EY, P Fong, JM Piulats, L Appleman, H Conter, S Feyerabend, N Shore, G Gravis, B Laguerre, H Gurney, M Retz, E Romano, L Mourey, JS de Bonno, A Kam, U Emmenegger, H Wu, C Poehlein, and W Berry, 2020, American Urological Association Annual Meeting

A multicenter phase IIb trial to evaluate the efficacy and tolerability of ModraDoc006/r in subjects with metastatic castration-resistant prostate cancer (mCRPC), suitable for treatment with a taxane (NCT04028388)
Vaishampayan, UN, EJ De Wit, ND Shore, R Dreicer, DJ George, RV Boccia, BD Curti, L Geczi, T Csõszi, and NJ Vogelzang, 2020, Genitourinary Cancers Symposium

PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase III trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients with localized high-risk or locally advanced prostate cancer (PC)
Taplin, M-E, M Gleave, CP Evans, E Efstathiou, PW Kantoff, A Ross, ND Shore, A Briganti, BA Hadaschik, A Heidenreich, OB Rooney, SK Tian, L Wetherhold, W Xu, S Cheng, SD Brookman-May, A Lopez-Gitlitz, and AS Kibel, 2020, Genitourinary Cancers Symposium

Concurrent or layered treatment (Tx) with radium-223 (Ra-223) and enzalutamide (Enza) or abiraterone plus prednisone/prednisolone (Abi/pred): A retrospective study of real-world clinical outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Shore, ND, OA Sartor, CN Sternberg, F Saad, BF Tombal, K Miller, J Kalinovsky, X Jiao, K Tangirala, and CS Higano, 2020, Genitourinary Cancers Symposium

An open-label phase Ib study of ORIC-101 in combination with enzalutamide in patients with metastatic prostate cancer progressing on enzalutamide
Shore, ND, R Patel, R Xu, PS Multani, Michael J. Morris, and W Abida, 2020, Genitourinary Cancers Symposium

Review of the real-world prevalence of mHSPC, nmCRPC, mCRPC, and gene alterations associated with HRR in prostate cancer (PC)
Shore, ND, L Oliver, I Shui, A Gayle, OY Wong, J Kim, S Payne, and SR Ghate, 2020, Genitourinary Cancers Symposium

Integrating comprehensive genomic profiling into the clinical management of prostate cancer patients: A single institution community practice experience
Shore, ND, J Haberberger, EA Severson, P Sathyan, P Reddy, and SH Ramkissoon, 2020, Genitourinary Cancers Symposium

Phase III study of pembrolizumab (pembro) plus docetaxel and prednisone for enzalutamide (enza)- or abiraterone acetate (abi)–pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-921
Shore, ND, Mostefa Bennamoun, R Ratta, JM Piulats, B Li, C Schloss, and K Fizazi, 2020, Genitourinary Cancers Symposium

HERO Phase 3 Trial: Results Comparing Relugoliz, an Oral GNRH Receptor Antagonist, vs Leuprolide Acetate for Advanced Prostate Cancer
Shore, N, F Saad, M Cookson, DJ George, DR Saltzstein, R Tutrone, H Akaza, A Bossi, D van Veenhuyzen, B Selby, X Fan, V Kang, J Walling, and B Tombal, 2020, American Urological Association Annual Meeting

Phase 3 Results of Vicinium in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Shore, N, M O’Donnell, T Keane, MAS Jewett, GS Kulkarni, R Dickstein, F Wolk, C Dunshee, L Belkoff, RL Dillon, J Cizeau, and W Kassouf, 2020, American Urological Association Annual Meeting

Impact of Baseline Disease Volume and Prior Docetaxel Therapy on Prostate-Specific Antigen-Related Outcomes in Patients with Metastatic Hormone-Sensitive Prostate Cancer Treated with Enzalutamide Plus Androgen Deprivation Therapy
Shore, N, ED Crawford, RZ Szmulewitz, D Petrylak, J Holzbeierlein, A Villers, A Azad, A Alcaraz, B Alekseev, T Iguchi, F Gomez-Veiga, B Rosbrook, B Baron, GP Haas, A Stenzl, and AJ Armstrong, 2020, American Urological Association Annual Meeting

Prostate Cancer Active Surveillance Quality in Large Community Urology Practices
Shelton, J, E Wood, T Paivanas, P Buffington, S Ruyle, E Cohen, R Natale, B Mehlhaff, R Suh, T Bradford, A Koo, L Kwan, and N Shore, 2020, American Urological Association Annual Meeting

Phase Ib study of niraparib plus androgen receptor-targeted therapy (ART) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Saad, F, KN Chi, ND Shore, JN Graff, EM Posadas, BM Espina, E Zhu, A Hazra, B Bradic, S Cheng, V Hayreh, and A Rezazadeh, 2020, Genitourinary Cancers Symposium

A comparison of sipuleucel-T (sip-T) product parameters from two phase III studies: PROVENT in active surveillance prostate cancer and IMPACT in metastatic castrate-resistant prostate cancer (mCRPC)
Ross, A, AJ Armstrong, Christopher M Pieczonka, JL Bailen, RF Tutrone, MR Cooperberg, CP Pavlovich, JF Renzulli, H Haynes, NA Sheikh, and ND Shore, 2020, Genitourinary Cancers Symposium

The association of humoral antigen spread (AgS) with cytotoxic T lymphocyte (CTL) activity after sipuleucel-T (sip-T) treatment in two phase II clinical studies: STAMP and STRIDE
Petrylak, DP, ES Antonarakis, H Kandadi, L Fong, RS Lance, T Vu, NA Sheikh, ND Shore, and CG Drake, 2020, Genitourinary Cancers Symposium

Next-generation sequencing (NGS) of tumor tissue from >4000 men with metastatic castration-resistant prostate cancer (mCRPC): The PROfound phase III study experience
Hussain, MHA, J Mateo, SK Sandhu, K Fizazi, F Saad, ND Shore, D Olmos, C Corcoran, C Sibilla, A Kohlmann, CA Adelman, JA Elvin, CD Goessl, J Burgents, and JS De Bono, 2020, Genitourinary Cancers Symposium

Can TURBT be Avoided? Primary Chemoablation with a Reverse Thermal Gel Containing Mitomycin (UGN-102) in Patients with Low Grade Intermediate Non-Muscle Invasive Bladder Cancer
Huang, W, K Chevli, A Trainer, A Smith, D Saltzstein, Y Ehrlich, B Friiedman, R D’Anna, D Morris, B Hu, M Tyson, A Sankin, M Kates, J Linehan, D Scherr, S Kester, M Verni, K Chemie, L Karsch, A Cinman, E Seltzer, N Gabai, R Kirshoff, M Schoenberg, J Raman, and N Shore, 2020, American Urological Association Annual Meeting

Clinical outcomes and patient (pt) profiles in REASSURE: An observational study of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC)
Higano, CS, F Saad, AO Sartor, K Miller, P Conti, DJ George, CN Sternberg, ND Shore, JP Sade, J Bellmunt, MR Smith, C Logothetis, F Verholen, J Kalinovsky, I Bayh, and BF Tombal, 2020, Genitourinary Cancers Symposium

Phase III study of perioperative pembrolizumab (pembro) plus cystectomy versus cystectomy alone in cisplatin-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC): KEYNOTE-905
Galsky, MD, A Necchi, ND Shore, F Witjes, K Nam, E Sbar, B Homet Moreno, and ER Plimack, 2020, Genitourinary Cancers Symposium

PROfound: Efficacy of olaparib (ola) by prior taxane use in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations
De Bono, JS, K Fizazi, F Saad, ND Shore, G Roubaud, M Ozguroglu, N Penel, N Matsubara, N Mehra, G Procopio, MP Kolinsky, K Nishimura, S Feyerabend, JY Joung, NJ Vogelzang, MA Carducci, J Kang, CH Poehlein, W Wu, and MHA Hussain, 2020, Genitourinary Cancers Symposium

KEYNOTE-365 cohort C updated results: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)
Berry, WR, PCC Fong, JM Piulats, LJ Appleman, HJ Conter, S Feyerabend, ND Shore, G Gravis, B Laguerre, H Gurney, M Retz, E Romano, L Mourey, JS De Bono, AE Kam, U Emmenegger, Helen Wu, Charles Schloss, Christian Heinrich Poehlein, and Evan Y. Yu, 2020, Genitourinary Cancers Symposium

TALAPRO-2: A placebo-controlled phase III study of talazoparib (TALA) plus enzalutamide (ENZA) for patients with first-line metastatic castration-resistant prostate cancer (mCRPC)
Agarwal, N, ND Shore, C Dunshee, LI Karsh, A Azad, AP Fay, J Carles, B Sullivan, N Di Santo, M Elmeliegy, X Lin, RGW Quek, A Czibere, and K Fizazi, 2020, Genitourinary Cancers Symposium

Lower ut symptoms due to benign prostatic hyperplasia
Shore, N.D.,

Z120920141
Francisco A. Myslicki, Jesse Shulman, Sharon Salenius, Neal Shore, Constantine Mantz, Eduardo Fernandez, Steven E. Finkelstein, 2015, ARS

Z050320161
Neal D. Shore, 2016, E-Cancer TV

mshoreurotoday
Neal D. Shore, 2017, LUGPA

mshore31618
Neal D. Shore, 2018, Urology Today

61520157
Myslicki FA, Salenius SA, Shore ND, Mantz CA, Fernandez E, Finkelstein SE, 2015, ACRO Annual Meeting

In the media

Low-grade prostate cancer should still be labelled cancer

September 9, 2022

View publication

ESMO 2022: Latest in PARP inhibitors for metastatic prostate cancer

September 13, 2022

View article 

LUGPA 2022: Dr. Shore on the significance of genetic testing in prostate cancer

November 9, 2022

View video

Neal D. Shore, MD, on Prostate Cancer: Biomarker Analysis, Enzalutamide, and Active Surveillance

2022

View video

Therapeutic Sequencing in View of Advanced Prostate Cancer Biology

2022

View article